Related Experiment Video

Updated: Jul 16, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.7K

Access to Medical Research is a Basic Human Right: A Roadmap to Research Integration Into a Practical Hepatocellular

Ahmed Omar Kaseb1

  • 1Department of Gastrointestinal Medical Oncology, Unit 426, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Journal of Hepatocellular Carcinoma
|April 2, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.0K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

358

Related Experiment Videos

Last Updated: Jul 16, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.7K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.0K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

358

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Nursing Ethical Principles II01:27

Nursing Ethical Principles II

Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's cancer...

Articles linked to this work by shared authors, journal, and citation graph.

Impact of Age on Patient-Reported Outcomes with First-Line Camrelizumab plus Rivoceranib versus Sorafenib in Adults with Unresectable Hepatocellular Carcinoma: Post Hoc Analyses of the CARES-310 Open-Label, Randomized, Phase 3 Trial.

Liver cancer·2026

Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.

Journal of immunotherapy and precision oncology·2024

Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma.

Oncology·2024

Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.

Cancer biomarkers : section A of Disease markers·2024

A Post-International Gastrointestinal Cancers' Conference (IGICC) Position Statements.

Journal of hepatocellular carcinoma·2024

Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma.

Oncology·2023

Efficacy Analysis of Capsule Integrity and TACE Combined with Microwave Ablation versus Microwave Ablation Alone for Primary Hepatocellular Carcinoma.

Journal of hepatocellular carcinoma·2026

Application of the AAPS (AFP-ALBI-PIVKA-II-Serum Albumin) Scoring System in Efficacy Monitoring of Hepatocellular Carcinoma Treated with PD-1 Inhibitor Combined with Transcatheter Arterial Chemoembolization (TACE).

Journal of hepatocellular carcinoma·2026

Association of Combined Iodine-125 Seed Implantation and Atezolizumab/Bevacizumab with Improved Outcomes in Recurrent Hepatocellular Carcinoma After Hepatectomy: A Comparative Retrospective Analysis.

Journal of hepatocellular carcinoma·2026

Shikonin in Hepatocellular Carcinoma: Bridging Metabolic Disruption and Immunomodulation.

Journal of hepatocellular carcinoma·2026

Multi-Target Tyrosine Kinase Inhibitors as Adjuvant Therapy for Hepatocellular Carcinoma Patients Who Achieve Complete Response After Transarterial Chemoembolization: A Real-World Study.

Journal of hepatocellular carcinoma·2026

From Tumor to Tumor-Spleen: MRI Habitat Heterogeneity for Predicting Immunotherapy Outcome in Advanced Hepatocellular Carcinoma.

Journal of hepatocellular carcinoma·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us